Does Trimethoprim-Sulfamethoxazole Prophylaxis for HIV Induce Bacterial Resistance to Other Antibiotic Classes?: Results of a Systematic Review by Sibanda, Euphemia L. et al.
HIV/AIDS MAJOR ARTICLE
Does Trimethoprim-Sulfamethoxazole
Prophylaxis for HIV Induce Bacterial Resistance
to Other Antibiotic Classes?: Results of
a Systematic Review
Euphemia L. Sibanda,1,3 Ian V.D. Weller,3 James G. Hakim,2 and Frances M. Cowan1,3
1Zimbabwe AIDS Prevention Project, Department of Community Medicine, College of Health Sciences, University of Zimbabwe, 2Department of
Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe; and 3Centre for Sexual Health & HIV Research, University College
London, London, United Kingdom
Background. Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis has long been recommended for
immunosuppressed HIV-infected adults and children born to HIV-infected women. Despite this, many resource-
limited countries have not implemented this recommendation, partly because of fear of widespread antimicrobial
resistance not only to TMP-SMX, but also to other antibiotics. We aimed to determine whether TMP-SMX
prophylaxis in HIV-infected and/or exposed individuals increases bacterial resistance to antibiotics other than
TMP-SMX.
Methods. A literature search was conducted in Medline, Global Health, Embase, Web of Science, ELDIS, and ID21.
Results. A total of 501 studies were identiﬁed, and 17 met the inclusion criteria. Only 8 studies were of high
quality, of which only 2 had been speciﬁcally designed to answer this question. Studies were classiﬁed as (1)
studies in which all participants were infected and/or colonized and in which rates of bacterial resistance were
compared between those taking or not taking TMP-SMX and (2) studies comparing those who had a resistant
infection with those who were not infected. Type 1 studies showed weak evidence that TMP-SMX protects
against resistance. Type 2 studies provided more convincing evidence that TMP-SMX protects against
infection.
Conclusion. There was some evidence that TMP-SMX prophylaxis protects against resistance to other
antibiotics. However, more carefully designed studies are needed to answer the question conclusively.
Trimethoprim-sulfamethoxazole (TMP-SMX) has been
shown to reduce HIV-related mortality among adults
and children when used as prophylaxis against oppor-
tunistic infections [1–4]. Since 2000, the World Health
Organization (WHO) and Joint United Nations Pro-
gramme on HIV/AIDS have recommended TMP-SMX
prophylaxis for immunosuppressed adults and children
born to HIV-infected women [5, 6].
The successful roll-out of antiretroviral drugs has
reduced the importance of TMP-SMX prophylaxis in
developed countries. However, in resource-limited set-
tings where antiretroviral therapy coverage is still in-
complete and where conﬁrmation of HIV infection in
children ,18 months of age is limited, TMP-SMX
prophylaxis remains vital for improving HIV manage-
ment outcomes.
Despite widespread recommendations and availabil-
ity of convincing evidence of the effectiveness of TMP-
SMX, the implementation of its use has been poor [7].
The WHO estimated that, in 2006, only 1% of the 4
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Zimbabwe in 2007, only 10.5% of children eligible for TMP-
SMX received it [9].
In Africa, barriers to implementation include shortages of
trained staff, stock-outs of TMP-SMX, and failure of health care
systems to identify individuals eligible for TMP-SMX pro-
phylaxis [7]. In addition, there is anxiety that it may not be
cost-effective. However new evidence of the intervention’s cost-
effectiveness may alleviate these concerns [10, 11].
Furthermore, there has been a concern that this intervention
will not work in areas where resistance to TMP-SMX is thought
to be high [7]. Fortunately, there is now convincing evidence
from South Africa and Zambia that it is effective even in these
settings, and indeed the beneﬁcial effects persist even as re-
sistance to TMP-SMX increases [7, 12, 13].
Of great importance has been the fear that blanket TMP-SMX
prophylaxis may lead to an increase in resistance to other drugs
besides TMP-SMX among common microbial pathogens [7, 14,
15]. There is evidence that TMP-SMX prophylaxis does not
increase resistance of Plasmodium falciparum to pyr-
imethamime-sulfadoxine [14, 16]. However, it remains unclear
whether TMP-SMX prophylaxis increases bacterial resistance to
other classes of antibiotics [7]. Biologically, when TMP-SMX
causes multidrug resistance, this is thought to be a result of
coselection and transference of antibiotic resistance genes be-
tween bacteria [17]. Conversely and indirectly, TMP-SMX
prophylaxis may reduce development of multidrug resistance by
preventing infections and, thereby, hospitalizations and expo-
sure to other antibiotics [7].
The aim of this systematic review was to evaluate the available
evidence with regard to whether TMP-SMX prophylaxis causes
an increase in bacterial resistance to other classes of antibiotics.
Froma public healthperspective,anincreaseinresistancewould
reduce the usefulness of current ﬁrst-line antibiotics and result
in reduced options for treating common bacterial infections in
developing countries. From an individual perspective, patients
receiving TMP-SMX prophylaxis may be at increased risk of
treatment failure when they acquire a bacterial infection, al-
though this has not been demonstrated in trials evaluating the
effectiveness of TMP-SMX.
METHODS
Publications were eligible for review if the study outcome in-
cluded a comparison of bacterial resistance to antibiotics other
than TMP-SMX between HIV-infected individuals or HIV-
exposed children receiving TMP-SMX prophylaxis and those
who were not.
Computersearcheswere conductedinthefollowing databases
on the Ovid Platform: Medline 1950 through week 4 June 2009,
Embase 1980 through week 27 2009, and Global Health 1910
through June 2009. Searches were also conducted in Web of
Science database (accessed 7–22 July 2009), ELDIS (accessed on
6 July2009), and ID21(accessed on6 July2009).Three concepts
derived from the research question were used for the literature
search: TMP-SMX prophylaxis, HIV infection, and antibiotic
resistance. The ﬁrst part of the search was an iterative process by
which the terms and synonyms that were relevant for the search
were determined. The search terms used on the Ovid Platform
are shown in Table 1. The search terms for Web of Science were
Topic5 (cotrimoxazole or co-trimoxazole or trimethoprim-
sulfamethoxazole or trimethoprim-sulphamethoxazole) and
Topic5 (prophyla*) and Topic5 (resist* or sensit* or suscep-
tib*) and Topic5 (‘‘human immunodeﬁciency virus’’ or HIV or
‘‘acquired immunodeﬁciency syndrome’’ or AIDS), in which *
represented truncation to ensure that the search was more in-
clusive. Web of Science was also used to ﬁnd publications that
had cited studies relevant to the topic. For the search platforms
in ELDIS and ID21, search terms including only the drug name
TMP-SMX and its synonyms were used.
Lastly, reference lists of all papers that were deemed to be
eligible during pilot searches were reviewed to identify any rel-
evant publications that may have been cited.
The titleand abstract (when available) of each publication were
reviewed for relevance to the topic. When it was obvious from the
title and/or abstract that a publication was not relevant, it was
eliminated. When it was less clear, the full paper was read to
determine whether it met all the inclusion criteria.
Eligible studies were reviewed for quality using quality as-
sessment tools that were adapted from the United Kingdom’s
National Institute for Health and Clinical Excellence (NICE)
guidelines [18, 19]. The tools were used to make a structured
assessment of whether a study was protected from bias and
confounding. Of interest in this aspect was the extent to which
studies took account of these confounders: (1) stage of HIV
disease, (2) previous hospitalization, and (3) previous antibiotic
use. Assessments were made on whether each study had internal
and external validity. A standardized form was used to extract
data. One person (ELS) reviewed and extracted the data, and
when there were uncertainties, advice was sought from one of
the co-authors.
The ﬁndings from the studies were synthesized, with more
credence being placed on studies that had fared better in the
quality assessment process. In theory, it would have been pos-
sible to meta-analyze the results from studies reporting methi-
cillin-resistant Staphylococcus aureus (MRSA) and studies
reporting pneumococcal resistance to penicillin. In practice,
however,the studiesthatexaminedpenicillinresistancereported
differing outcomes; thus, it was not possible to combine them. It
was possible to conduct separate meta-analyses for case-control,
cross-sectional, and cohort studies of infection and/or coloni-
zation with MRSA.
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A total of 501 studies were identiﬁed, of which 17 remained
eligible for inclusion. Figure 1 shows the elimination process for
the reviewed studies.
Description of Studies
Six cohort studies [16, 17, 20–23], 4 case-control studies [24–
27], 6 cross-sectional studies [28–33], and 1 before-after study
[34] met the eligibility criteria (Table 2). Six studies were con-
ducted in the United States, 4 in SouthAfrica, 2 in Italy, and 1 in
each of the following countries: Kenya, Zambia, Singapore,
Spain, and France.
Only 2 studies [16, 17] were designed to determine whether
TMP-SMX prophylaxis increases antibiotic resistance. The re-
mainder examined the question as subanalyses of studies which
had been designed to answer a different question.
There were 2 comparison groups for bacterial resistance to
antibiotics other than TMP-SMX: studies in which all participants
were infected and/or colonized and in which rates of bacterial
resistance were compared between those taking or not taking
TMP-SMX. Most type 1 studies reported on pneumoccocal re-
sistance to penicillin. Type 2 studies compared those who had
a resistant infection/colonization with those who were not in-
fected/colonized. Most type 2 studies reported on infection and/or
colonization with MRSA.
Description of the Quality of Studies
Studies that did not control for confounders of interest (stage of
HIV disease, prior hospitalization, and previous antibiotic use)
were considered to be of poorer quality. Only 8 [16, 17, 20, 23,
25, 26, 29, 31] of the 17 studies were considered to have pro-
tection from bias and confounding. The rest of the studies were
not necessarily poorly conducted, but they had not been de-
signed to primarily answer the question of this review. Only 4
studies [17, 22, 30, 32] involved children: 3 involved HIV-
infected children and 1 involved HIV-exposed infants [17].
Synthesis of Findings From the Studies
When looking at the study ﬁndings according to type of com-
parison group, 10 studies [16, 17, 21, 22, 26, 27, 30, 32–34] were
considered to have type 1 comparisons, and 7 [20, 23–25, 28, 29,
31] were considered to be type 2. Of type 1 studies, 4 [16, 17, 30,
33] were colonization studies (1 MRSA and 3 pneumococcal), 4
[21, 22, 27, 32] investigated infection (1 MRSA, 2 pneumo-
coccal, and 1 various organisms), and 2 [26, 34] investigated
both colonized and infected patients. Two of the 4 colonization
studies [30, 33], neither of which were considered to be good
quality (1 pneumococcal and 1 MRSA), reported increased
colonization with drug-resistant bacteria. One good-quality
study [16] reported no change, and another good-quality study
[17] reported mixed ﬁndings; among HIV-exposed infants,
TMP-SMX prophylaxis increased pneumococcal resistance to
clindamycin but had no effect on pneumococcal resistance to
penicillin, tetracycline, erythromycin, and chloramphenicol. Of
the 4 infection studies, 2 [22](1 [27] MRSA and 1 pneumo-
coccus, neither considered to be good quality) reported no
difference in rate of infection with drug-resistant pneumococ-
cus, and 1 [21] (not considered to be good quality) reported an
increase. One study [32] had too few isolates to allow mean-
ingful interpretation of the results despite presenting the num-
ber of drug-resistant isolates in each group (TMP-SMX vs no
TMP-SMX). The 2 studies (1 good quality [26]) that in-
vestigated both colonized and infected patients reported in-
creases in infection and/or colonization with drug-resistant
bacteria.
The 2 studies (both type 1) [16, 17] that had been designed
speciﬁcally to answer the question of this review showed no
change in pneumococcal resistance to penicillin. However, one
of these studies reported resistance to clindamycin among HIV-
exposed infants, as described above [17].
Of type 2 studies, 4 investigated MRSA infection [20, 23–
25], 2 investigated colonization with MRSA [29, 31], and 1
reported on colonization with vancomycin-resistant
Table 1. Search Terms on the Ovid Platform
Concept 1: cotrimoxazole prophylaxis Concept 2: HIV infection Concept 3: antibiotic resistance
Cotrimoxazole adj6
b prophyla
a HIV or AIDS Resist
a
Co-trimoxazole adj6 prophyla
a MeSH terms (speciﬁc
for each database)
Bacteri
a adj6 sensitiv
a or
bacteri adj6 susceptib
a
Trimethoprim-sulfamethoxazole adj6 prophyla
a The above terms were
combined with operator "or"
The above terms were
combined with operator ‘‘or’’
Trimethoprim-sulphamethoxazole adj6 prophyla
a
Bactrim adj6 prophyla
a
Septrin adj6 prophyla
a
MeSH terms (speciﬁc for each database)
All the above terms were combined with operator ‘‘or’’
NOTE. Results from Concept 1, Concept 2 and Concept 3 were brought together using the operator ‘‘and’’.
a is a truncation sign.
b adj6 means the two terms are within six words of each other.
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[20, 23, 25] of the 4 MRSA infection studies reported a re-
duction in infection with MRSA, and 1 (not considered to be
good quality) reported an increase in MRSA infection. The
type 2 colonization studies reported no change [31]and re-
duced colonization [29] for 2 MRSA studies, whereas there
was reported increase in colonization with vancomycin-
resistant enterococcus [28].
Of the type 2 MRSA studies, there was signiﬁcant heteroge-
neity among both the cross-sectional and case-control studies,
and thus, no meta-analyses are presented. However, for cohort
studies, the meta-analysis showed a protective effect of TMP-
SMX prophylaxis on MRSA (relative risk, .29; 95% conﬁdence
interval, .12 - 0.7) (Figure 2); the test for heterogeneity among
cohort studies was not signiﬁcant (P 5 .92).
In an analysis of results according to whether the study out-
come was colonization or infection, no trends were seen in the
data, possibly because there were small numbers in each of the
categories. In addition, no trends were noted in analysis of
whether the study population comprised adults or children,
because only 3 child studies were included in the synthesis, and
they all had different results.
Figure 1. Process for identification of eligible publications.
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Results
Author
Study location
Study design Study population and size
Comparison group (Type 1
or Type 2)
c Reported outcomes
Prevalence of antibiotic
resistance by group or
Relative Risk/Odds Ratio
(95% Cl) Study conclusions
Crum-Cianﬂone et al 2007
[20]
USA Cohort
HIV-positive adult
outpatients with controls
who were not on CTX.
Duration on CTX not
given. N5435
Type 2 Community-acquired
infection with Methicillin-
Resistant Staphylococcus
Aureas (MRSA)
CTX50/29 (0%) CNTL549/
404 (12%) P5.06 RR not
reported
CTX Y MRSA
Mathews et al 2005 [23]
USA Cohort
HIV-positive adult patients
who had been on CTX for
at least 120 days. Con-
trols had been on CTX for
less than 120 days (ref-
erence in RR calculation).
N53,455
Type 2 Initial episode of clinically
signiﬁcant
b MRSA in-
fection during the study
period
Prevalence not reported
Unadjusted RR 0.4
a
Adjusted RR .3 (0.1–.7)
b
aNo conﬁdence interval
given for unadjusted
effect
bAdjusted for race, HIV
disease progression, and
antiretroviral drug
therapy
CTX Y MRSA infection
Jordano et al 2004 [21]
Spain Cohort
HIV-positive adult patients
(duration on CTX not
given), with controls who
were not on CTX. N557
Type 1 Infection with pneumococcal
bacterial strains with
resistance to penicillin
CTX560%
c CNTL538.5%
P5.09 RR not reported
cNo numbers given
CTX [ pneumococcal
resistance to penicillin
Hamel et al 2008
a [16]
Kenya Cohort
HIV-positive adults with
low CD41 cells. Ex-
posed to CTX for six
months. N51,160
Type 1 Among patients colonized
with pneumoccocus,
comparison of preva-
lence of pneumococcal
resistance to penicillin at
baseline with that at 6
months after initiation of
CTX prophylaxis
CTX585% CNTL585% RR
not reported
No change in pneumococ
cal resistance to
penicillin
Gill et al 2008
a [17] Zambia
Cohort
Infants born to HIV-positive
mothers who were given
CTX from six weeks of
age and followed up to
age 18 months (HIV-ex-
posed infants) with HIV-
unexposed infants as
controls. N5260
Type 1 Among infants colonized
by S. Pneumoniae
comparison of resis-
tance levels to each of
the following drugs:
clindamycin, penicillin,
erythromycin, tetracy-
cline, chloramphenicol
Prevalence not reported
Unadjusted RR
d; 1.6
(1.0–2.6)
d 1.1 (0.7–1.7)
1.0 (0.6–1.7) 0.9 (0.6–
1.5) 0.8 (0.3–2.3)
dRR are
for each of the following
drugs respectively:
Clindamycin, penicillin,
erythromycin, tetracycline,
Chloramphenicol
RR remained the same
after adjusting for
confounders
[ resistance to clindamycin
but no change in
pneumococcal
resistance to penicillin,
erythromycin,
tetracycline,
and Chloramphenicol
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Author
Study location
Study design Study population and size
Comparison group (Type 1
or Type 2)
c Reported outcomes
Prevalence of antibiotic
resistance by group or
Relative Risk/Odds Ratio
(95% Cl) Study conclusions
Madhi et al 2000 [22] South
Africa cohort
HIV-positive children.
Controls were also HIV
positive who were not on
CTX for unspeciﬁed rea-
sons. Duration on CTX
not given. N5146.
Type 1 Infection with S. Pneumo-
niae resistant to penicillin,
cefotaxime, TMP-SMX,
tetracycline, chloram-
phenicol, erythromycin,
clindamycin, rifampicin
Cotrimoxazole prophylaxis
had no impact on re-
sistance to other anti-
biotics, no other data
given
CTX had no impact on
pneumococcal resistance
to other antibiotics
Drapeauet al2007[24]Italy
case-control
HIV-positive patients
admitted to a hospital in
Italy. Duration on CTX
not given. N581
Type 2 Cases were deﬁned as HIV-
positive patients who
developed clinically sig-
niﬁcant
b MRSA infection.
Controls were HIV-posi-
tive patients who did not
develop MRSA
Prevalence not applicable
Unadjusted OR 3.06
(.99–9.41) Adjusted OR
not given
CTX [ MRSA
Lee et al 2005 [25] USA
case-control
HIV-positive MSM
receiving care at three
participating clinics in
Los Angeles County.
Duration on CTX not
given. N5111
Type 2 A case was the onset of
a culture-positive MRSA
skin infection in an HIV-
positive MSM. A control
was an HIV-positive
MSM without skin
symptoms
Prevalence not applicable
Unadjusted OR
.3 (0.1–.9)
Adjusted OR .2
(0.1–.8)
f
fAdjusted for history of
hospitalization, race and
ethnicity, and number of
sex partner
CTX Y MRSA
Meynard et al 1996 [26]
France case-control
Hospitalised HIV-positive
patients. Duration on
CTX not given. N545
Type 1 Cases were patients with
S. Pneumoniae isolates
that were intermediately
or fully resistant to peni-
cillin; and controls were
patients with S. Pneu-
moniae isolates that
were susceptible to pen-
icillin
Prevalence not applicable
Unadjusted OR
5.0 (1.9–13.3)
Adjusted OR: 4.4
(1.6–7.0)
g
4.9 (2.1–11.7)
h
gAdjusted for CD41 count
hAdjusted for previous
hospitalization
CTX [ pneumococcal
resistance to penicillin
Tumbarello et al 2002 [27]
Italy case-control
HIV-infected patients aged
.18 years with S. aureus
bacteremia. Duration on
CTX not given N5129
Type 1 Cases were HIV-positive
patients with MRSA
bacteremia and controls
were deﬁned as HIV-
positive patients with
MSSA bacteremia
Prevalence not applicable
Unadjusted OR
.76 (.36–1.60)
Adjusted OR not given
CTX had no impact on
MRSA
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Author
Study location
Study design Study population and size
Comparison group (Type 1
or Type 2)
c Reported outcomes
Prevalence of antibiotic
resistance by group or
Relative Risk/Odds Ratio
(95% Cl) Study conclusions
Achenbach et al 2006 [28]
USA cross-sectional
HIV-positive adults, some
on CTX and some not.
Duration on CTX not
given. N585
Type 2 Prevalence of colonization
with vancomycin re-
sistant enterococcus
The only data presented is
that colonization with re-
sistant bacteria was as-
sociated with TMP-SMX
prophylaxis, P5.05
CTX [ resistance of en-
terococcus to penicillin
Cenizal et al 2008 [29] USA
cross-sectional
HIV-positive adults, some
on CTX and some not.
Duration on CTX not
given. N5146
Type 2 Prevalence of nasal coloni-
zation with MRSA
CTX50/29 (0%) CNTL515/
102 (15%) P5.04
CTX Y MRSA
Cotton et al 2008 [30] South
Africa cross-sectional
HIV-positive children, some
on CTX and some not.
Duration on CTX not
given. N5203
Type 1 Nasal colonization with
S. Aureus
CTX: 87% CNTL: 70%
P5.002 RR not reported
CTX [ MRSA
Pemba et al 2008 [33] South
Africa cross-sectional
HIV-positive mine workers,
some on CTX and some
not. Duration on CTX not
given. N5856
Type 1 Prevalence of penicillin
resistant Pneumococcus
among patients who
were colonized
CTX57/23 (30%) CNTL5
4/49(8%)Unadjusted RR
4.92 (1.27–19.7)
Adjusted RR not given
CTX [ pneumococcal re-
sistance to penicillin
Villacian et al 2004 [31]
Singapore cross-sectional
HIV-positive adults, some
on CTX and some not.
Duration on CTX not
given. N5195
Type 2 Prevalence of colonization
with MRSA
Prevalence not reported
Unadjusted RR
19.4 (1.2–347.4
Adjusted RR values not
given, but after adjust-
ment for confounders
TMP-SMX was not as-
sociated with MRSA
CTX had no impact on
MRSA
Zar et al 2003 [32] South
Africa cross-sectional
HIV-positive children, some
on TMP-SMX and some
not. N5151
Type 1 Five different bacterial
pathogens were cul-
tured: K. Pneumonia;
S.Aureus H. Inﬂuenza, S.
Pneumonia, M.Catar-
rhalis. Prevalence of re-
sistance of each
organism to 3 or 4 dif-
ferent drugs was de-
termined.
Data not presented in a way
that allowed in-
terpretation for this re-
view: Of the
pneumoccocal isolates
from children taking pro-
phylaxis, two were sensi-
tive, three were
intermediately resistant
and one was resistant to
penicillin. The single iso-
late from a child not on
prophylaxis was penicillin-
sensitive.
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Prevalence of antibiotic
resistance by group or
Relative Risk/Odds Ratio
(95% Cl) Study conclusions
Martin et al 1999 [34] USA
before-after
Hospital patients. Antibiotic
resistance levels were
compared between the
period during (n519,514,
30,886 cultures) and one
before (n not given,
24,884 cultures) wide-
spread implementation
of TMP-SMX pro-
phylaxis.
Type 1 Resistance of E.Coli and
S. Aureas species among
colonized or infected
HIV-positive individuals
werecomparedbetween
two periods
CTX572%; CNTL541%
l
CTX514%, CNTL50%
m
CTX521%; CNTL50%
n
CTX516%; CNTL54%
o
CTX514%; CNTL50%
p
RR not reported
l,mResistance of E. Coli
to ampicillin and
cephazolin respectively.
n,o,pResistanceofS. Aureas
to ciproﬂoxacin, nafcillin
and gentamicin re-
spectively.
In E. Coli and S. Aureas
HIV-infected patients with
CTX resistance were sig-
niﬁcantly more likely to
display resistance to other
antibiotics.
CTX [ Resistance of E. Coli
and S. Aureus
NOTE. CTX5Cotrimozaxole; CNTL5Control; MRSA5Methicillin Resistant Staphylococcus Aureas, MSSA5Methicillin Susceptible Staphylococcus Aureas,R R 5Relative Risk, OR5Odds Ratio, MSM5Men having
sex with men, CD415CD41 T lymphocyte count.
a The study was designed to look at the effect of TMP-SMX prophylaxis on resistance levels.
b Clinically signiﬁcant infection-Generally described in the speciﬁed papers as clinician diagnosis of infection as opposed to colonisation, and isolation of bacteria from a normally sterile body site.
c 15Comparison group is based on having sensitive bacterial infection/colonisation; 25comparison group is based on having no infection/colonisation at all.
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Seventeen of 501 studies identiﬁed met the eligibility criteria of
this review. Of 8 studies that were considered to have fair pro-
tection from bias and confounding, only two studies had been
designed to evaluate the effect of TMP-SMX prophylaxis on
antibiotic resistance.Inthe remainderofthe studies,the effectof
TMP-SMX was examined in subanalyses, which often had low
precision.
The studies could be classiﬁed according to types of com-
parison group:type 1were studiesinwhichtheanalysisincluded
patients who were all infected/colonized and comparisons of
antibiotic resistance levels were made between those receiving
TMP-SMX and those who were not; type 2 studies straight-
forwardly compared patients who developed a drug-resistant
infection/colonization with those who had no infection/
colonization. No patterns were seen in the type 1 studies. Of 3
studies that were considered to be good quality in this group, 1
reported no change in pneumococcal resistance after TMP-SMX
use, 1 reported an increase in resistance, and 1 reported mixed
ﬁndings: an increase in pneumocccal resistance to clindamycin
but no change in resistance to 4 other drugs.
For the type 1 studies, it may be appropriate to place addi-
tional weight on the 2 cohort studies that were speciﬁcally de-
signed to evaluate the effect of TMP-SMX prophylaxis on
antibiotic resistance [16, 17]. The rationale for this is 2-fold:
ﬁrst,cohortstudiesarethe mostrobustdesignsforobservational
studies, because they are the least likely to have bias and con-
founding. Second, because the studies were designed to evaluate
the effectofTMP-SMXonantibioticresistance, theyarelikelyto
produce more reliable resultsthan smaller subanalyses of studies
designed to answer a different question.
Gill et al compared HIV-exposed infants with HIV-un-
exposed infants [17]. There is evidence that HIV-exposed in-
fants are colonized and infected more than HIV-unexposed
patients [22, 35, 36]. There is also evidence that HIV-infected
individuals are more likely to be colonized and infected by an-
tibiotic-resistant bacteria [30]. In accordance with this, com-
parison of HIV-exposed and nonexposed children should show
that HIV-exposed children have higher antibiotic resistance lev-
els. However, the ﬁndings by Gill et al do not show this expected
difference in 4 of 5 classes of antibiotics that were investigated,
possibly because TMP-SMX has a protective effect, which makes
HIV-exposed children similar to HIV-unexposed children [17].
Carefully designed observational studies to test this theory should
be conducted in low-income countries where TMP-SMX pro-
phylaxis is recommended for HIV-exposed children.
In contrast to type 1 studies, for type 2 studies, there was
stronger evidence that TMP-SMX prophylaxis protects from
infection with drug-resistant bacteria. Four studies, all consid-
ered of good quality, reported reduced infection and/or colo-
nization with MRSA, and 1 study, also of good quality, reported
no change in colonization with MRSA. The 2 lower-quality
studies in this group reported increased MRSA. The meta-
analysis of MRSA cohort studiesrevealed a 70% protective effect
of TMP-SMX prophylaxis from MRSA infection (relative risk,
.29; 95% conﬁdence interval, .12–.7)
It is plausible that TMP-SMX prophylaxis protects against
infection with drug-resistant bacteria. TMP-SMX may directly
protect against colonization and/or infection with drug-sus-
ceptible bacterial pathogens [3], and indirect protection may
arise as a result of this as the individual is less exposed to con-
ditions that have been found to be risk factors for infection and/
or colonization with drug-resistant bacteria. For example, the
patient may no longer need frequent hospitalization or will be
lesslikely tobe exposed tointravenous catheters,conditionsthat
have been shown to increase antibiotic resistance [31]. As a re-
sult, the patient may be less likely to receive other antibiotics for
treatment of infections, and such exposure to antibiotics has
been shown to increase antibiotic resistance [27].
TheﬁndingbyGilletalthatpneumococcalresistanceto1of5
antibiotics increased whereas there was no change in the re-
sistancelevelsfortheother4 drugs might meanthatitispossible
for TMP-SMX prophylaxis to increase bacterial resistance to
some classes of antibiotics but not to others [17]. This may be
feasible if the mechanism of development of resistance to TMP-
SMX is linked to that of the other antibiotic. Multidrug re-
sistance can be horizontally transferred between bacterial species
and genus borders ifthe genes that codefor multidrugresistance
are located on transferable plasmids or transposons [37]. It has
beenproposedthatTMP-SMX prophylaxis may cause resistance
to clindamycin or penicillin through co-selection of linked an-
tibiotic resistance genes. [17, 26]
The strength of the Hamel et al [16] study is that it was
adjusted for baseline antibiotic resistance levels. Results
from that study suggest that there is no effect of 6 months of
Figure 2. Meta-analysis of MRSA cohort studies.
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exposed HIV-infected adults. This may also be explained by
possible protection of TMP-SMX from infections, as explained
above. Of note, the 2 studies that were designed to answer the
question of this review reported no change in pneumococcal
resistance to penicillin.
The meta-analysis of studies relating to colonization and/or
infection with MRSA shows the potential effect of differing
study designs on resistance outcomes. The 2 cohort studies (ie,
the most robust studies) clearly showed reduced MRSA colo-
nization and/or infection, both individually and when com-
bined, whereas the cross-sectional and case-control studies
showed no effect.
This literature review had several limitations. Because TMP-
SMX prophylaxis has long been proven to save lives of HIV-
infected patients, only observational studies, which have more
potential for bias and confounding, were available for review.
Most studies did not control for factors that are known to in-
dependently increase antibiotic resistance. For example, only 3
studies adjusted for HIV disease progression or previous hos-
pitalization. Previous hospitalization has been reported as an
important risk factor for colonization or infection with MRSA
[24, 25, 38].
Most studies did not provide data on the duration of expo-
sure to TMP-SMX prophylaxis. Of the studies that did, the
duration of exposure is shorter than expected in clinical practice
in resource-limited settings. Because of the shortage of anti-
retroviral therapy in such settings, HIV-infected adults are likely
to be receiving TMP-SMX prophylaxis for much longer periods
than was evaluated in these studies. However, the ﬁnding from
Gill et al may be more generalizable to HIV-exposed infants,
because TMP-SMX was given according to guidelines used in
many resource-limited settings [17].
Most studies only evaluated resistance to 1 antibiotic. This
makesitdifﬁculttoknowwhetherﬁndingscan beappliedacross
different antibiotic classes.
The other limitation of the review was the heterogeneity of
study designs, class of bacteria, and drug classes investigated,
which makes comparing study ﬁndings problematic and makes
it inappropriate to conduct a meta-analysis for all studies.
CONCLUSIONS AND RECOMMENDATIONS
After placing weight on good-quality studies and additional
weight on studies that were speciﬁcally designed to determine
whether TMP-SMX prophylaxis increases antibiotic resistance,
the ﬁndings of this review offer suggestive evidence that TMP-
SMX prophylaxis for opportunistic infections in HIV protects
against development of bacterial resistance to other classes of
antibiotics.Morecarefullydesignedstudiesshouldbe conducted
to answer this question. It is important to ensure that future
studies evaluate the importance of duration of exposure to
TMP-SMX on antimicrobial resistance.
Ideally, microbial resistance surveys should be included with
TMP-SMX implementation in developing countries to alert
providers to any changes in drug resistance patterns.
Of most importance, the fear of antibiotic resistance should
not stop health care providers from giving TMP-SMX to in-
dividuals who need it.
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